Drug Name:
ANALPRAM HC 1% Rx

Generic Name and Formulations:
Hydrocortisone acetate 1%, pramoxine HCl 1%; crm.
Company:
Sebela Pharmaceuticals Inc.
Therapeutic Use:
Indications for ANALPRAM HC 1%:
Corticosteroid–responsive dermatoses.
Adults and Children:
Apply thin film 3–4 times daily.
Contraindications:
Do not use superpotent forms on face, groin, or axillae. Exclude viral disease (eg, chickenpox, measles).
Warnings/Precautions:
Treat infection if present; discontinue if infection persists or worsens. Do not use near eyes, or on diaper dermatitis or pre-existing skin atrophy. Do not use fluorinated steroids longer than 1 week on the face. Avoid abrupt cessation in chronic use. Systemic absorption increased by broken or inflamed skin, prolonged use, application to large surface area, or use of occlusive dressings. Occlude only if necessary; do not occlude higher potency products. Monitor adrenal function in children if a high potency product or occlusion is used, and in adults if more than 50g weekly of a high potency product is used. Discontinue or reduce dose or potency if HPA axis suppression, Cushing's syndrome, hyperglycemia, glucosuria, or irritation occurs. Use lowest effective dose and potency (esp. in children). Use caution if applying to face or body folds. Do not use continuously or for prophylaxis. Foams are flammable. Reevaluate periodically. Pregnancy (Cat.C). Nursing mothers.
See Also:
Adverse Reactions:
Burning, stinging, pruritus, erythema, skin atrophy, striae, miliaria, secondary infections, hypopigmentation, folliculitis, hypertrichosis, acneiform eruptions, dermal cracking and fissuring, telangiectasia, contact dermatitis, other local effects, immunosuppression, masks infections, HPA axis suppression (esp. in children).
How Supplied:
Crm—30x4g, 1oz
Lotion—60mL
Sign Up for Free e-newsletters
ONA Articles
- FDA: Number of U.S. Women With Breast Implant-Caused Cancer Has Increased
- Immunotherapy for HER2-positive Breast Cancer: Recent Advances and Combination Therapeutic Approaches
- Nurse-Led vs Oncologist-Led Breast Cancer Follow-up Program: Early Feasibility Results of an Ongoing Study
- A Review of Clinical Outcomes in Patients With Early-Stage Burkitt Lymphoma
- Survey Demonstrates Relationship Between Symptom Burden, Medical Disability Leave Among Myeloproliferative Neoplasms
- Oncology Nurse Navigation Facilitates Timely Treatment of Pancreatic Cancer
- Substitute for Lidocaine
- Oncology Nurses Weigh In on Their Patient-Centered Communication Practices, Needs
- FDA: Number of U.S. Women With Breast Implant-Caused Cancer Has Increased
- Identifying the Needs of Multidisciplinary Team Treating Geriatics Cancer Patients
- Hypofractionated Radiotherapy for Prostate Cancer: The New ASTRO/ASCO/AUA Guideline
- Risk of Hospitalization Remains High for Survivors of Childhood Leukemia
- Sequence of Immunotherapy, Targeted Therapy, Radiation Therapy Influences Overall Survival in Melanoma Brain Metastases
- Survey Demonstrates Implicit Bias Toward Cervical Cancer Diagnoses Among Nurses, Women
- Use of Watchful Waiting Up for Low-Risk Localized Prostate Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
Bone Cancer | Regimens | Drugs |
Brain Cancer | Regimens | Drugs |
Breast Cancer | Regimens | Drugs |
Endocrine Cancer | Regimens | Drugs |
Gastrointestinal Cancer | Regimens | Drugs |
Genitourinary Cancer | Regimens | Drugs |
Gynecologic Cancer | Regimens | Drugs |
Head and Neck Cancer | Regimens | Drugs |
Hematologic Cancer | Regimens | Drugs |
Lung Cancer | Regimens | Drugs |
Other Cancers | Regimens | |
Rare Cancers | Regimens | |
Skin Cancer | Regimens | Drugs |